Navigation Links
Onyx Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/2/2011

60;210,142$195,372License revenue

-59,165-59,165Total revenue

75,041122,861210,142254,537Operating expenses:Research and development (1) (2)58,53244,568184,071131,394Selling, general and administrative (1)42,64225,924115,34977,293Contingent consideration

5,9455,62223,195101,107Lease termination exit costs

130-10,857-Total operating expenses

107,24976,114333,472309,794Income (loss) from operations

(32,208)46,747(123,330)(55,257)Investment income

4356281,7282,198Interest expense

(5,112)(4,943)(15,155)(14,467)Other income (expense) (3)

25(862)(3,776)(862)Income (loss) before provision (benefit) for income taxes

(36,860)41,570(140,533)(68,388)Provision (benefit) for income taxes

-7032(662)Net (loss) income

$(36,860)$41,500$ (140,565)$ (67,726)Net (loss) income per share:Basic

$
(0.58)$
.66$
(2.22)$
(1.08)Diluted (4)$
(0.58)$
.66$
(2.22)$
(1.08)Computation of diluted shares:Basic

63,55562,70763,32862,562Dilutive effect of options

-142--Diluted (4)63,55562,84963,32862,562(1)Includes employee stock-based compensation charges of:Research and development

$
,988$   1,075$
4,808$
3,090Selling, general, and administrative

6,6854,79917,56513,502Total employee stock-based compensation

$
8,673$   5,874$
22,373$   16,592(2)
Includes a $12.7 million non-cash expense related to the unamortized balance of funding provided to S*BIO which was recorded in the first quarter of 2011.

(3) Includes a $3.0 million impairment charge which reflects the reassessment of the fair value of Onyx's equity investment in S*BIO during the first quarter of 2011.

(4) Under the "if-converted" method, interest and issuance costs and potential common shares related to the Company's convertible senior notes were excluded in the computation of diluted per share amounts for the three and
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Mexico , Dec. 24, 2014  Novastem, ... of its first patient in its study for ... the American Stroke Association, ischemic strokes account for ... to enroll qualified patients in the study, entitled ... Administration of Allogeneic Mesenchymal Stem Cells and Intrathecal ...
(Date:12/24/2014)...  Commonwealth Cornerstone Group (CCG) today announced the completion of ... to help fund the expansion and consolidation of healthcare services ... . PHN is the largest federally ... It is the largest employer in Sharon,s ... staff. Currently, PHN Sharon offers scattered services out ...
(Date:12/24/2014)... , Dec. 24, 2014 Kinex Pharmaceuticals announced ... KX2-361 at Roswell Park Cancer Institute. KX2-361 ... drug that has shown potent inhibitory activity against a ... that are resistant to Temozolomide (T98G), the most widely ... a well-established brain tumor mouse model, KX2-361 consistently clears ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3
... Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO ) today ... Total revenue was $2.6 million and $8.2 million for the ... million and $3.8 million for the same periods in 2010. ... September 30, 2011, were $9.0 million and $24.0 million as compared ...
... UCB today announced new ... (certolizumab pegol) was associated with a rapid and sustained ... of moderate to severe rheumatoid arthritis (RA) patients. The ... 2011 Annual Scientific Meeting in Chicago, November 5-9, are ...
Cached Medicine Technology:Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 2Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 3Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 4Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 5Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 6Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 7Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 8Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 9New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 2New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 3New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 4New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 5New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 6New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 7New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 8New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 9New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 10New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 11
(Date:12/26/2014)... December 26, 2014 Yisrayl Hawkins, Pastor at ... open letter in light of the Ferguson, Missouri unrest. Yisrayl ... civil unrest and explains why it has only increased. ... was even created. He says there is a very specific ... also says there is a set of rules, or Laws ...
(Date:12/26/2014)... (PRWEB) December 26, 2014 Pentec Health, ... in the state of Pennsylvania for 2014. The awards ... statewide programs of its kind in the country. The ... the Pennsylvania Department of Community and Economic Development, the ... Management and the Central Penn Business Journal. ...
(Date:12/25/2014)... The click strand woven bamboo flooring ... Today, the business announces a click strand woven ... 30, 2015. , Click strand woven bamboo flooring ... a well-known brand in the bamboo industry. It ... reliable bamboo flooring supplier. , “We are happy ...
(Date:12/25/2014)... the popular online supplier of wedding dresses and special occasion ... black one-shoulder cocktail dresses . In addition, all these elegant ... prices, up to 70% off. , The development ... You know, we have thousands of frequent callers in the ... can visit our website for more details. The current special ...
(Date:12/25/2014)... California (PRWEB) December 25, 2014 Helen ... home in Woodland Hills, California after an 8 year ... away on Christmas Eve evening in her home in ... aggressive metastatic breast cancer. , As ... over forty years, she pioneered and championed many of ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... Improving Healthcare , , PLANO, Texas, Dec. 5 Edition 1 ... Vice President and Chief Medical, ... Vice President for Marwood Group, What: "Looking Forward: Perspectives ... hosted by Dr. Harry Greenspun, Executive Vice President and, ...
... another reason to quit smoking, consider that it may diminish ... the University of Rochester Medical Center have found that women ... were significantly more likely to face fertility problems and suffer ... non-smoking women showed those who were exposed to second hand ...
... The board of directors,for Hillenbrand, Inc. (NYSE: ... of $0.185 per share on the company,s common stock, ... $0.1825 per share. The dividend,is payable Dec. 31, 2008, ... Dec. 17, 2008. Hillenbrand has paid quarterly dividends since ...
... at 62nd Annual Meeting of the American Epilepsy Society , ... New studies presented at the 62nd annual meeting of the ... the course of epilepsy diagnosis and management to improve the ... These studies are among the hundreds of developments in the ...
... State Budget Crisis Threaten Seniors, Access to Quality Care, LTC ... Dec. 5 Commenting on the legislative year ahead ... comments today that skilled nursing facilities (SNFs) should not receive ... the nation,s leading long term care advocacy organizations today said ...
... skills , , FRIDAY, Dec. 5 (HealthDay News) -- College students ... might want to get some sleep instead. And not just ... test. , That,s the message from a new study that ... you learn during the day. , Study participants who learned ...
Cached Medicine News:Health News:Looking Forward: Perspectives on Healthcare and Information Technology 2Health News:Looking Forward: Perspectives on Healthcare and Information Technology 3Health News:Secondhand smoke raises odds of fertility problems in women 2Health News:New Research Reports on Interventions that May Alter the Course of Epilepsy Diagnosis and Management 2Health News:New Research Reports on Interventions that May Alter the Course of Epilepsy Diagnosis and Management 3Health News:New Research Reports on Interventions that May Alter the Course of Epilepsy Diagnosis and Management 4Health News:New Research Reports on Interventions that May Alter the Course of Epilepsy Diagnosis and Management 5Health News:Long Term Care Sector Supports and Is Well-Positioned to Advance Health Care Reform, Bolster Economic Stimulus 2Health News:Long Term Care Sector Supports and Is Well-Positioned to Advance Health Care Reform, Bolster Economic Stimulus 3Health News:To Sleep, Perchance to Remember 2Health News:To Sleep, Perchance to Remember 3
Platelet Aggregation Profiler...
... Eclipse,Plus or 850 ECG medical ... capability. Doctors,maintain all the benefits ... and gain the,ability to view ... personal computers., With diagnostic-quality viewing ...
... The Vision5L Digital ... 5- or 7-lead, ... a signal preview,screen. ... using a compact,flash ...
... provides three contrast levels (high, 9.5 % and ... This test is designed to detect very subtle ... lens evaluation or due to refractive surgery. The ... same contrast and acuity levels as the lower ...
Medicine Products: